S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NYSE:EW

Edwards Lifesciences (EW) Stock Forecast, Price & News

$84.08
+0.12 (+0.14%)
(As of 06/9/2023 ET)
Compare
Today's Range
$83.24
$84.55
50-Day Range
$81.42
$89.18
52-Week Range
$67.13
$107.92
Volume
2.15 million shs
Average Volume
3.13 million shs
Market Capitalization
$50.97 billion
P/E Ratio
34.89
Dividend Yield
N/A
Price Target
$90.00

Edwards Lifesciences MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
7.0% Upside
$90.00 Price Target
Short Interest
Healthy
1.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.65mentions of Edwards Lifesciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$18.20 M Sold Last Quarter
Proj. Earnings Growth
12.55%
From $2.55 to $2.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

200th out of 987 stocks

Surgical Appliances & Supplies Industry

7th out of 18 stocks


EW stock logo

About Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Receive EW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

EW Stock News Headlines

The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Analysts Set Edwards Lifesciences Co. (NYSE:EW) PT at $90.00
8-K: Edwards Lifesciences Corp
See More Headlines

EW Price History

EW Company Calendar

Last Earnings
4/26/2023
Today
6/09/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
28176E10
Employees
17,300
Year Founded
1958

Price Target and Rating

Average Stock Price Forecast
$90.00
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+7.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
18 Analysts

Profitability

Net Income
$1.52 billion
Pretax Margin
31.45%

Debt

Sales & Book Value

Annual Sales
$5.38 billion
Cash Flow
$2.75 per share
Book Value
$9.39 per share

Miscellaneous

Free Float
598,398,000
Market Cap
$50.97 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Bernard J. ZovighianBernard J. Zovighian
    President, Chief Executive Officer & Director
  • Scott B. UllemScott B. Ullem
    Chief Financial Officer & Vice President
  • Todd J. Brinton
    Chief Scientific Officer & VP-Advanced Technology
  • Linda J. Park
    Secretary, Senior VP & Associate General Counsel
  • Larry L. WoodLarry L. Wood
    Vice President













EW Stock - Frequently Asked Questions

Should I buy or sell Edwards Lifesciences stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View EW analyst ratings
or view top-rated stocks.

What is Edwards Lifesciences' stock price forecast for 2023?

18 brokerages have issued 12-month price objectives for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they expect the company's stock price to reach $90.00 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price.
View analysts price targets for EW
or view top-rated stocks among Wall Street analysts.

How have EW shares performed in 2023?

Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have increased by 12.7% and is now trading at $84.08.
View the best growth stocks for 2023 here
.

Are investors shorting Edwards Lifesciences?

Edwards Lifesciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 9,840,000 shares, an increase of 7.2% from the April 30th total of 9,180,000 shares. Based on an average daily trading volume, of 3,100,000 shares, the days-to-cover ratio is currently 3.2 days. Approximately 1.6% of the shares of the company are short sold.
View Edwards Lifesciences' Short Interest
.

When is Edwards Lifesciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our EW earnings forecast
.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Co. (NYSE:EW) announced its earnings results on Wednesday, April, 26th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. The medical research company earned $1.46 billion during the quarter, compared to analyst estimates of $1.39 billion. Edwards Lifesciences had a net margin of 27.07% and a trailing twelve-month return on equity of 25.81%. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 EPS.
Read the conference call transcript
.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences's stock split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were payable to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What guidance has Edwards Lifesciences issued on next quarter's earnings?

Edwards Lifesciences updated its FY23 earnings guidance on Wednesday, April, 26th. The company provided earnings per share (EPS) guidance of $2.48-$2.60 for the period, compared to the consensus EPS estimate of $2.51. The company issued revenue guidance of $5.6-$6.0 billion, compared to the consensus revenue estimate of $5.85 billion.

What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO?

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

What is Edwards Lifesciences' stock symbol?

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.51%), State Street Corp (4.44%), Bank of New York Mellon Corp (3.00%), Wellington Management Group LLP (2.61%), Brown Advisory Inc. (2.32%) and Geode Capital Management LLC (2.01%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends
.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edwards Lifesciences' stock price today?

One share of EW stock can currently be purchased for approximately $84.08.

How much money does Edwards Lifesciences make?

Edwards Lifesciences (NYSE:EW) has a market capitalization of $50.97 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.41 on an earnings per share basis.

How many employees does Edwards Lifesciences have?

The company employs 17,300 workers across the globe.

Does Edwards Lifesciences have any subsidiaries?
The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.
Read More
How can I contact Edwards Lifesciences?

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525.

This page (NYSE:EW) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -